Skip to Content

Zimmer Biomet Holdings Inc ZBH Stock Quote

| Rating as of

NYSE:ZBH

Morningstar‘s Stock Analysis ZBH

Valuation
Currency in USD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

Capital Allocation

INVESTOR

Zimmer Biomet Is Well Positioned for the Postpandemic Environment; No Change to Our FVE

Debbie S. Wang Senior Equity Analyst

Business Strategy and Outlook

| Debbie S. Wang |

With the addition of Biomet, Zimmer is the undisputed king of large joint reconstruction, by far. We expect favorable demographics, which include aging baby boomers and rising obesity, to fuel solid demand for large-joint replacement that should offset price declines. However, Zimmer stumbled into a series of pitfalls in 2016-2017, including integration issues, supply and inventory challenges, and quality concerns. New management's efforts to turn around the firm have been admirable, but the pandemic has put a damper on progress.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics ZBH

Company Profile ZBH

Business Description

Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.

Contact
345 East Main Street
Warsaw, IN, 46580
T +1 574 267-6131
Industry Medical Devices
Most Recent Earnings Sep 30, 2022
Fiscal Year End Dec 31, 2022
Employees 19,500

Related News ZBH